StockData

Avalo Therapeutics vs Entera Bio

AVTX and ENTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AVTX and ENTX compare

Entera Bio is the larger company, worth 1.3 times as much as Avalo Therapeutics ($523M against $395M).

Avalo Therapeutics scores higher on the StockData Score (8 against 6 for Entera Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAVTXENTX
Size and price
Market cap$395M$523M
Share price$7.37$3.02
Change, 1 year−50.0%10.2%
Change, 5 years−99.9%−12.0%
Beta (5Y)2.19−0.35
Employees2320
StockData Score
Total score8 (better)6
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score66
Dividend score00
Valuation
P/B0.9× (better)72.0×
FCF yield–−2.1%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average−61.2%−35.1% (better)
EPS growth, 5Y average–−17.9%
Profitability
Return on equity−36.3% (better)−139%
Return on invested capital–−966%
Financial health
Debt / equity0.000.00
Current ratio19.31 (better)8.98
Altman Z-score4.5214.49 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield–−0.01%
Shareholder yield0.00% (better)−0.01%
Ownership
Held by institutions135%6.2%
Held by insiders0.71%11.3%
Insider net buying, 12 months−$8.3M$141K (better)
Short interest, % of float16.7%4.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.